Company Description
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications.
It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
In addition, it is developing CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies.
The company is headquartered in Agoura Hills, California.
Country | Canada |
IPO Date | Aug 26, 1993 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 22 |
CEO | Dr. Vuong Trieu Ph.D. |
Contact Details
Address: 29397 Agoura Rd., #107 Aguora Hills, California 91301 United States | |
Phone | 650-635-7000 |
Website | oncotelic.com |
Stock Details
Ticker Symbol | OTLC |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000908259 |
CUSIP Number | 628341109 |
ISIN Number | US6283411097 |
Employer ID | 13-3679168 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Vuong Trieu Ph.D. | Chairman and Chief Executive Officer |
Amit Shah | Chief Financial Officer |
Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D. | Chief Clinical Officer of Translational Medicine and Director |
Saranjit Saund | CBO and GM of AI Division |
Steven W. King | Consultant and Director |
Dr. Larn Hwang | Chief Scientific Officer |
Dr. Seymour Howard Fein M.D. | Chief Medical Officer |
Burcak Beser | Chief Technology Officer of AI Division |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 15, 2024 | 10-Q | Quarterly Report |
Apr 29, 2024 | 8-K | Current Report |
Apr 26, 2024 | 424B3 | Prospectus |
Apr 22, 2024 | EFFECT | Notice of Effectiveness |
Apr 18, 2024 | POS AM | Post-Effective amendments for registration statement |
Apr 12, 2024 | POS AM | Post-Effective amendments for registration statement |
Apr 12, 2024 | 10-K | Annual Report |
Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
Feb 2, 2024 | 8-K | Current Report |
Nov 14, 2023 | 10-Q | Quarterly Report |